UTMD:NASDAQUtah Medical Products, Inc. Analysis

Utah Medical Products is trading just below its 20‑day SMA of 67.17 and essentially at its 50‑day SMA of 65.41, while the 200‑day SMA sits at 61.06, indicating a short‑term price compression within a longer‑term uptrend. The RSI of 47 suggests neutral momentum, but the MACD line is negative and the histogram is below zero, flagging a bearish signal in the near term. Support at 64.16 is comfortably above the recent low of 64.4, yet the next resistance at 71.81 appears distant given the current price of 65.4. Volatility over the past 30 days is elevated at 28.6% while the beta of 0.56 points to lower market sensitivity, balancing the risk profile. Fundamentally, the company posts strong profitability with a 28.9% profit margin and a healthy cash pile of $87.4 M against negligible debt, supporting its 1.93% dividend yield. The trailing P/E of 19.35 is well below the industry average of 26.68, and the P/B of 1.75 underscores a modest valuation premium. Revenue has contracted by roughly 10%, but margins remain robust, and the dividend payout ratio of 36% appears sustainable. Recent Q1 earnings showed a modest profit of $2.6 M, reinforcing the earnings consistency despite the revenue dip. Overall, the stock sits at a valuation sweet spot with solid cash, low leverage, and an attractive dividend, but technical indicators warn of short‑term downside pressure. Investors should weigh the bullish fundamentals against the bearish near‑term momentum before deciding on entry timing.